Javascript Disabled

This site requires Javascript in order to function properly. Please enable it in your browser's settings.

To reduce serum phosphate in patients with ESRD FOSRENOL Chewable Tablets:
Prescribed by nephrologists for more than a decade

  • When managing ESRD patients, you want to know that your prescribing decisions are backed by substantial clinical-trial evidence
  • FOSRENOL, approved in 2004, has been studied in clinical trials involving 5200+ patients1,2

Indication

FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).

Please click here for Full Prescribing Information .

Important Safety Information

Indication

FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).

Please click here for Full Prescribing Information.

References: 1. Center for Drug Evaluation and Research. FOSRENOL approval letter. US Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/21468ltr.pdf. Published October 26, 2004. Accessed March 29, 2015. 2. FOSRENOL [package insert]. Lexington, MA: Shire US Inc.